Posted On: 5/29/2020 10:57 AM
Merck 010- A Phase 3, Randomized Open-label study of Pembrolizumab plus Olaparib versus Abiraterone Acetate or Enzalutamide
Patients who are unselected for HRR defects and have failed prior treatment w/one NHA AND Chemotherapy.
Sponsored by: Merck
Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.
Research Department (315) 478-4185, option 3